Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | LPL | P06858 | 12/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16669514 | 1.00 | ESR2 (0.49) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL16394141 | 1.00 | ESR2 (0.49) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL14804365 | 0.92 | LPL (0.52) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL16112310 | 0.92 | LPL (0.52) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL2016127 | 0.85 | LPL (0.46) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL20428742 | 0.85 | ESR2 (0.49) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL2017546 | 0.85 | LPL (0.46) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL2016128 | 0.85 | LPL (0.46) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL3136657 | 0.85 | HIF1A (0.49) | ESR2LPLLIPGHIF1AF11 | |
| SCHEMBL3708268 | 0.85 | LPL (0.49) | ESR2LPLLIPGHIF1AF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063148-B1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3063148-B1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3022210-B1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-9492436-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| EP-3063148-A1 | AZABENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2016-09-07 | — | — | EP | disclosed |
| EP-3022210-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| WO-2015063011-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| WO-2015007669-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | PRKAR2B, PRKAB1, PRKAB2 | ESR2 440/4885LPL 2227/4885LIPG 2389/4885 |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | PRKAR2B, PRKAB2, PRKAB1 | ESR2 293/4885LPL 1759/4885LIPG 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.